NO20065859L - Bruk av IL-17 behandlingen av fertilitetsrelaterte lidelser - Google Patents

Bruk av IL-17 behandlingen av fertilitetsrelaterte lidelser

Info

Publication number
NO20065859L
NO20065859L NO20065859A NO20065859A NO20065859L NO 20065859 L NO20065859 L NO 20065859L NO 20065859 A NO20065859 A NO 20065859A NO 20065859 A NO20065859 A NO 20065859A NO 20065859 L NO20065859 L NO 20065859L
Authority
NO
Norway
Prior art keywords
treatment
fertility
related disorders
present
methods
Prior art date
Application number
NO20065859A
Other languages
English (en)
Norwegian (no)
Inventor
Stephen S Palmer
Ann M Clark
David Kagan
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20065859L publication Critical patent/NO20065859L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pregnancy & Childbirth (AREA)
NO20065859A 2004-05-28 2006-12-19 Bruk av IL-17 behandlingen av fertilitetsrelaterte lidelser NO20065859L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57532604P 2004-05-28 2004-05-28
PCT/US2005/018952 WO2005117979A2 (en) 2004-05-28 2005-05-31 Use of il-17 in the treatment of fertility-related disorders

Publications (1)

Publication Number Publication Date
NO20065859L true NO20065859L (no) 2007-02-28

Family

ID=35463365

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065859A NO20065859L (no) 2004-05-28 2006-12-19 Bruk av IL-17 behandlingen av fertilitetsrelaterte lidelser

Country Status (8)

Country Link
US (1) US20080014172A1 (de)
EP (1) EP1765083A4 (de)
JP (1) JP2008501035A (de)
AU (1) AU2005249504A1 (de)
CA (1) CA2565801A1 (de)
IL (1) IL179463A0 (de)
NO (1) NO20065859L (de)
WO (1) WO2005117979A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005292362B2 (en) * 2004-09-30 2012-05-31 Merck Serono Sa Use of IL-17- for maturation of oocytes
FR2904553A1 (fr) * 2006-08-03 2008-02-08 Isthmes Group Res And Innovati Procede de fabrication d'un materiau biocompatible implantable integrant une substance therapeutique et materiau biocompatible implantable obtenu par un tel procede
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
WO2011000805A1 (en) * 2009-06-29 2011-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarkers of oocyte competency and method of use
EP2493506B1 (de) 2009-10-30 2019-04-10 Janssen Biotech, Inc. Il-17a-antagonisten
EP2348318A1 (de) * 2010-01-21 2011-07-27 Equipo Ivi Investigación, S.L. Verfahren zur Diagnose der endometrialen Rezeptivität
GB201013343D0 (en) * 2010-08-09 2010-09-22 Queen Mary & Westfield College Compositions and methods for inducing platelet aggregation
GB201314452D0 (en) * 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
CA2937970A1 (en) * 2014-02-11 2015-08-20 Qingling Yu Immunotherapeutic composition, method of treatment, and method of diagnosis
US11129851B2 (en) 2014-06-17 2021-09-28 Igenomix S.L. Stem cell therapy in endometrial pathologies
RU2685554C1 (ru) * 2018-05-07 2019-04-22 Федеральное государственное бюджетное научное учреждение "Дальневосточный научный центр физиологии и патологии дыхания" Способ оценки нарушения имплантации эмбриона при беременности, осложненной цитомегаловирусной инфекцией, путем определения циклооксигеназы-2 в гомогенате ворсинчатого хориона
CN113403259B (zh) * 2021-06-04 2023-01-17 华南农业大学 一种提高克隆胚胎发育质量的添加剂及其应用
CN118684781A (zh) * 2023-03-21 2024-09-24 深圳赫兹生命科学技术有限公司 GnRH-VLP重组去势疫苗及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053337A (en) * 1989-10-30 1991-10-01 Neurogenetic Corporation DNA encoding an α2B -adrenergic receptor
US5661024A (en) * 1989-10-31 1997-08-26 Synaptic Pharmaceutical Corporation DNA encoding a human serotonic (5-HT2) receptor and uses thereof
US5155218A (en) * 1990-05-08 1992-10-13 Neurogenetic Corporation Dna encoding human 5-ht1d receptors
AU672768B2 (en) * 1991-12-02 1996-10-17 Lundbeck Research Usa, Inc. DNA encoding a human 5-HT-1E receptor and uses thereof
US5360735A (en) * 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
EP1063292A3 (de) * 1992-09-25 2001-04-25 Synaptic Pharmaceutical Corporation Für menschliche alpha-1-adrenerge rezeptoren kodierende dns und ihre verwendung
US5472866A (en) * 1992-12-24 1995-12-05 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4A serotonin receptors
US5516653A (en) * 1993-12-28 1996-05-14 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
US5545549A (en) * 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5602024A (en) * 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
NZ306653A (en) * 1995-03-23 1999-03-29 Immunex Corp Isolated dna il-17 receptors
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
CA2277519A1 (en) * 1997-01-10 1998-07-16 Massachusetts Institute Of Technology Treatments for neurotoxicity in alzheimer's disease by .beta.-amyloid peptides
US6569645B2 (en) * 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6579520B2 (en) * 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
US20020182673A1 (en) * 1998-05-15 2002-12-05 Genentech, Inc. IL-17 homologous polypedies and therapeutic uses thereof
US6047848A (en) * 1998-10-22 2000-04-11 Davis; Rex C. Collapsible container
EP1022027A1 (de) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Antagonisten von Tumornecrosefaktor und ihre Verwendungen gegen Endometriose
WO2001081922A2 (en) * 2000-04-19 2001-11-01 Research Corporation Technologies, Inc. Diagnostic assay for endometriosis
US20030124092A1 (en) * 2001-06-21 2003-07-03 Eugene Medlock IL-17 like molecules and uses thereoflike molecules and uses thereof

Also Published As

Publication number Publication date
IL179463A0 (en) 2007-05-15
US20080014172A1 (en) 2008-01-17
WO2005117979A2 (en) 2005-12-15
EP1765083A4 (de) 2008-08-20
JP2008501035A (ja) 2008-01-17
WO2005117979A3 (en) 2006-03-02
EP1765083A2 (de) 2007-03-28
AU2005249504A1 (en) 2005-12-15
CA2565801A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
NO20092637L (no) Fremgangsmater for behandling
TW200510416A (en) P38 inhibitors and methods of use thereof
NO20064852L (no) Azaindoler som er nyttige som inhibitorer av jak og andre proteinkinaser
CY1112790T1 (el) Χρηση μαγιας σεληνιου στην αντιμετωπιση της νοσου αλτσχαιμερ
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
EA200870019A1 (ru) Лактамовые соединения и способы их применения
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
NO20071742L (no) Kinazoliner som er nyttige som modulatorer av ionekanaler
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
IL181629A0 (en) Compositions and methods for the diagnosis and tretment of tumor
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
TNSN07005A1 (fr) Analogues tetrapeptidiques
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
MY160041A (en) Compositions and methods for treating parasitic infections
NO20054546L (no) Kinazoliner anvendelige som modulatorer av ionekanaler
NO20071378L (no) Tiazolo-naftylsyrer.
EP1804761A4 (de) Zusammensetzungen und verfahren zur behandlung von hautverfärbungen
NO20065859L (no) Bruk av IL-17 behandlingen av fertilitetsrelaterte lidelser
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
TW200738669A (en) Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide
NO20054371L (no) Somatostatin-dopamin kimaere analoger

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application